Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rashmi K Murthy

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
The Oncologist|August 25, 2018
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted TherapyYao Wong, Akshara Singareeka Raghavendra, Christos Hatzis, et al.
Cancer|January 28, 2012
An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancerPhuong Khanh Morrow, Rashmi K Murthy, Joe D Ensor, et al.
Investigational New Drugs|January 28, 2018
A phase II study of tipifarnib and gemcitabine in metastatic breast cancerClinton Yam, Rashmi K Murthy, Vicente Valero, et al.
Clinical Immunology (Orlando, Fla.)|March 1, 2019
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumorsG Travis Clifton, Kaitlin M Peace, Jarrod P Holmes, et al.
The Oncologist|February 1, 2020
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without TrastuzumabTakahiro Kogawa, Takeo Fujii, Jimin Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast CancerG Travis Clifton, Diane Hale, Timothy J Vreeland, et al.
The Lancet. Oncology|May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studyKenji Tamura, Junji Tsurutani, Shunji Takahashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2020
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib StudyShanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Cancer|March 29, 2014
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancerRashmi K Murthy, Ankur Varma, Priyankana Mishra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2020
Reply to T.J.A. DekkerShanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
The Oncologist|August 25, 2018
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted TherapyYao Wong, Akshara Singareeka Raghavendra, Christos Hatzis, et al.
Cancer|January 28, 2012
An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancerPhuong Khanh Morrow, Rashmi K Murthy, Joe D Ensor, et al.
Investigational New Drugs|January 28, 2018
A phase II study of tipifarnib and gemcitabine in metastatic breast cancerClinton Yam, Rashmi K Murthy, Vicente Valero, et al.
Clinical Immunology (Orlando, Fla.)|March 1, 2019
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumorsG Travis Clifton, Kaitlin M Peace, Jarrod P Holmes, et al.
The Oncologist|February 1, 2020
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without TrastuzumabTakahiro Kogawa, Takeo Fujii, Jimin Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast CancerG Travis Clifton, Diane Hale, Timothy J Vreeland, et al.
The Lancet. Oncology|May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studyKenji Tamura, Junji Tsurutani, Shunji Takahashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2020
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib StudyShanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Cancer|March 29, 2014
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancerRashmi K Murthy, Ankur Varma, Priyankana Mishra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2020
Reply to T.J.A. DekkerShanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Pageof 5